UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038056
Receipt number R000043351
Scientific Title The effect of compression therapy using surgical gloves on taxane-induced peripheral neuropathy(randomized control trial)
Date of disclosure of the study information 2019/11/01
Last modified on 2019/09/19 15:24:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of compression therapy using surgical gloves on taxane-induced peripheral neuropathy(randomized control trial)

Acronym

compression therapy(taxane)

Scientific Title

The effect of compression therapy using surgical gloves on taxane-induced peripheral neuropathy(randomized control trial)

Scientific Title:Acronym

compression therapy(taxane)

Region

Japan


Condition

Condition

lung cancer, gastric cancer, esophageal cancer, breast cancer, endometrial cancer, cervical cancer, ovarian cancer, pancreatic cancer

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

evaluate the efficacy of compression therapy with Surgical Gloves for prevention of taxane-induced neuropathy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

The incidence of taxane-induced peripheral neuropathy grade 2 or higher using the CTCAE version 5.0.

Key secondary outcomes

The incidence of peripheral neuropathy grade B,C,D,E using Patient Neurotoxicity Questionnairethe (PNQ).
The incidence of skin and nail tissue disorders using the CTCAE version 5.0. Time to skin and nail tissue disorders
The incidence of taxane-induced peripheral neuropathy grade 1.3.4 using the CTCAE version 5.0.
Time to peripheral neuropathy
Ratio of cases dropping out


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Compression therapy with surgical Gloves all cycle from 30 minutes before administration of taxane therapy to 30 minutes after administration

Interventions/Control_2

no preventation

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with lung cancer, gastric cancer, esophageal cancer, breast cancer, endometrial cancer, cervical cancer, ovarian cancer, and pancreatic cancer who receive taxane-containing-regimen

porfomance status 0-2
patients who do not have latex allergy
Taxane naive
patients who got written informed consent

Key exclusion criteria

patients who have CTCAE more than grade1 neuropathy

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Takuya
Middle name
Last name Suyama

Organization

Hitachi general Hospital

Division name

hematology,oncology

Zip code

317-0077

Address

2-1-1 Jonan-cho,Hitachi City,Ibaraki prefecture

TEL

0294231111

Email

sutaku2468@yahoo.co.jp


Public contact

Name of contact person

1st name Takuya
Middle name
Last name Suyama

Organization

Hitachi general hospital

Division name

hematology,oncology

Zip code

317-077

Address

2-1-1 Jonan-cho,Hitachi City,Ibaraki prefecture

TEL

0294231111

Homepage URL


Email

sutaku2468@yahoo.co.jp


Sponsor or person

Institute

Hitachi general hospital

Institute

Department

Personal name



Funding Source

Organization

Hitachi General Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hitachi General Hospital

Address

2-1-1 Jonan-cho,Hitachi City,Ibaraki prefecture

Tel

0294231111

Email

sutaku2468@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2019 Year 07 Month 19 Day

Date of IRB


Anticipated trial start date

2019 Year 11 Month 01 Day

Last follow-up date

2024 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 19 Day

Last modified on

2019 Year 09 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043351


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name